

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-66190
		<b>Application Number</b>	10/607,598
		<b>Filing Date</b>	June 27, 2003
		<b>First Named Inventor</b>	Martin
		<b>Art Unit</b>	1646- 1647
		<b>Examiner Name</b>	Not yet assigned J. Seharaseyon
JS		Package insert for Zenapax (Daclizumab), December 1997.	
		Paty et al., "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis," <i>Neurology</i> 43:662-667 (1993)	
		Posey et al., "TCP presents its annual list of drugs in development and what their approval will mean to long-term care patients," <a href="http://www.ascp.com/public/pubs/tcp/1997/apr/newdrugs.html">www.ascp.com/public/pubs/tcp/1997/apr/newdrugs.html</a> , June 4, 2002.	
		Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> 86 (24): 10029-10033, 1989.	
		Samkoff, Lawrence, "Multiple Sclerosis: Update of Treatment," <i>Hospital Physician</i> pp. 21-27, 2002.	
		"Study of Zenapax in the treatment of multiple sclerosis," <a href="http://www.mult.sclerosis.org/news/Nov2000/ZenapaxMS.html">www.mult.sclerosis.org/news/Nov2000/ZenapaxMS.html</a> , November 27, 2000.	
		Waldmann, et al., "Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy," <i>Hematology</i> (1): 394, 2000.	
		Wandinger et al., "Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes," <i>Ann. Neurol.</i> , 50(3):349-57 (2001).	

<b>EXAMINER SIGNATURE:</b>	/Jegatheesan Seharaseyon/	<b>DATE CONSIDERED:</b>	07/28/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			